Anjeanette Ormonde

Oct 21, 2024 | outsourcedpharma.com | Louis Garguilo |BioPlan Associates |Ioanna Deni |Anjeanette Ormonde

It’s not magic -- it’s science. With KBI Biopharma’s SUREmAb™ solution, your mAb development moves faster and smarter. Get minimum titers of 4 g/L and up to 10g/L for your IgG monoclonal antibodies before process optimization and tox material in just 6.5 months from transfection—guaranteed. Built on the SUREtechnology Platform™, powered by Selexis®, that has enabled bringing over 110 mAbs to clinic and 7 to market. Set your mAb program on the fast track.

Aug 20, 2024 | bioprocessonline.com | Tyler Menichiello |Anjeanette Ormonde |Natasha Savage |Joonman Hong

Derisking Biomanufacturing: Why A CDMO In Poland Might Be Your Secret WeaponAs the U.S. government works to pass the BIOSECURE Act, which aims to the protect the IP of U.S. pharma companies, the EU is simultaneously seeking to increase innovation across the European biomanufacturing industry. Amid these cultural shifts, sponsors are considering the best global partnerships for their goals.